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Abstract
Background: Circulating immune cells including autoreactive T cells and monocytes have been documented as key players
in maintaining, protecting and repairing the central nervous system (CNS) in health and disease. Here, we hypothesized that
neurodegenerative diseases might be associated, similarly to tumors, with increased levels of circulating peripheral myeloid
derived suppressor cells (MDSCs), representing a subset of suppressor cells that often expand under pathological conditions
and inhibit possible recruitment of helper T cells needed for fighting off the disease.
Methods and Findings: We tested this working hypothesis in amyotrophic lateral sclerosis (ALS) and its mouse model,
which are characterized by a rapid progression once clinical symptoms are evident. Adaptive transfer of alternatively
activated myeloid (M2) cells, which homed to the spleen and exhibited immune suppressive activity in G93A mutant
superoxide dismutase-1 (mSOD1) mice at a stage before emergence of disease symptoms, resulted in earlier appearance of
disease symptoms and shorter life expectancy. The same protocol mitigated the inflammation-induced disease model of
multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), which requires circulating T cells for disease
induction. Analysis of whole peripheral blood samples obtained from 28 patients suffering from sporadic ALS (sALS),
revealed a two-fold increase in the percentage of circulating MDSCs (LIN
2/LowHLA-DR
2CD33
+) compared to controls.
Conclusions: Taken together, these results emphasize the distinct requirements for fighting the inflammatory
neurodegenerative disease, multiple sclerosis, and the neurodegenerative disease, ALS, though both share a local
inflammatory component. Moreover, the increased levels of circulating MDSCs in ALS patients indicates the operation of
systemic mechanisms that might lead to an impairment of T cell reactivity needed to overcome the disease conditions
within the CNS. This high level of suppressive immune cells might represent a risk factor and a novel target for therapeutic
intervention in ALS at least at the early stage.
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Introduction
Amyotrophic lateral sclerosis (ALS), commonly known as Lou
Gehrig’s disease, is an adult-onset neurodegenerative disease that
selectively destroys upper and lower motoneurons, resulting in
muscle weakness and atrophy, progressive paralysis, respiratory
failure, and eventually death within 4–6 years [1,2,3]. The role of
peripheral immune cells in this devastating disease has only been
recently appreciated. Several studies suggest that boosting
peripheral immunity, rather than suppressing it, might allow for
better recruitment of circulating immune cells to sites of
neurological damage, thereby ameliorating local toxic inflamma-
tory effects and possibly augmenting protective responses adjacent
to injured neurons [4,5,6,7]. More recently, studies investigating
the systemic immune system of sALS patients revealed changes in
peripheral blood T cells [8,9,10], monocytes, and in chemokine
receptor 2 (CCR2) expression levels on monocytes [9,11],
suggesting an important role for elements of the immune system
in ALS patients.
Myeloid-derived suppressor cells (MDSCs) constitute a unique
component of the immune system that regulate immune responses
in healthy individuals and in various diseases [12]. Yet, like any
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26921Figure 1. Shorter survival times and earlier appearance of disease symptoms following repeated administration of IL-4 treated
BMDM. (A–B) Male mSOD1 mice on a B6/SJL genetic background receiving repeated injections of IL-4-activated BMDM starting from day 70 (early
BMDMIL-4) had a shorter survival time (12762 days, n=13) than non-injected mSOD1 control littermates (13863 days, n=11; P=0.003, log-rank-sum
test). Survival of male mSOD1 mice receiving repeated IL-4-activated BMDM starting from day 90 (late BMDMIL-4) was similar to control mSOD1
littermates (13563 days, n=14; P=0.515). (C) Effects of early and late treatment with IL-4-activated BMDM on Rotarod performance compared to
control mice. Rotarod performance in mice with early treatment declined at most time points, between 109 and 150 days of age, compared with
untreated control mSOD1 littermates (P,0.0001, one-way ANOVA; each pair Student’s t test, *early vs. control; 1 late vs. control; #early vs. late). (D)
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may be detrimental rather than helpful. For example, in cancer,
peripheral immunosuppressive cells may increase over the course
of tumor development [13,14,15], contributing to an escape from
immune system surveillance and increased tumor proliferation.
Our hypothesis is that such a dysregulation of the immune
response may also play an important role in neurodegenerative
diseases such as sALS, and thus could be a disease risk factor. In
mice, MDSCs are characterized by the co-expression of the
myeloid-cell lineage differentiation antigen Gr1 and CD11b.
Normal mouse bone marrow contains 20–30% of cells with this
phenotype, but these cells make up only a small proportion (2–4%)
of spleen cells and are absent from the lymph nodes [12]. Another
population of myeloid cells that exhibit suppressive activity is the
alternatively activated macrophages, designated M2 macrophages.
These cells share many characteristics of tumor-associated
macrophages (TAMs), which help the tumor to escape from
immune-mediated killing [16]. In humans, MDSCs are most
commonly defined as cells that express the common myeloid
marker CD33 but lack the expression of markers of mature





Here, we show that systemic administration of IL-4 treated bone
marrow-derived myeloid cells (BMDM) to G93A mutant super-
oxide dismutase-1 (mSOD1) mice (ALS mice) before emergence of
disease symptoms resulted in earlier appearance of disease
symptoms and shorter life expectancy, while the same protocol
mitigated the inflammation-induced disease model of multiple
sclerosis, experimental autoimmune encephalomyelitis (EAE).
Analysis in patients suffering from ALS revealed a two-fold




+) in sporadic ALS (sALS) patients
compared to controls.
Results
To test our working hypothesis that systemic myeloid-derived
suppressor cells might have a role in ALS, we first examined the
potential ability of such cells to affect the kinetics of disease onset
and progression in ALS mice. Suppressive activity of myeloid-
derived suppressor cells in humans was shown to be mediated by
the enzyme arginase 1 (Arg1), which can be induced in myeloid-
derived cells by IL-4. Therefore, we used IL-4 activated BMDM
cells in our attempts to modify the disease course. In order to
examine the impact of these cells on both disease onset and
progression, we repeatedly injected mSOD1 mice intravenously
(i.v) with IL-4-activated BMDM from day 70 onward, every fifth
day (early BMDMIL-4). As controls, we used a group of non-
injected mSOD1 mice (control), a group of mSOD1 mice that
received the same cells starting on day 90 (late BMDMIL-4), and a
group of mSOD1 mice that received IFNc-activated BMDM from
day 70 onward (early BMDMIFNc). Survival of mSOD1 mice
receiving early treatment with IL-4-activated BMDM cells was
shorter compared to control, untreated mice (P=0.003, log-rank-
sum test), and compared to mSOD1 mice receiving late treatment
with the same cells (P=0.012, log-rank-sum test; FIGURE 1A–B).
The median survival of mSOD1 mice receiving early treatment
with IL-4 activated BMDM was 127d, compared to 141d for
control mice and 135d for mice receiving late treatment with IL-4
activated BMDM cells. Similarly, early treatment of mSOD1 mice
with IL-4-activated BMDM cells resulted in earlier appearance of
clinical symptoms compared to mice receiving late treatment and
to control untreated mice, as monitored by a decline in Rotarod
performance (P,0.0001, 2-factor repeated measures ANOVA;
FIGURE 1C). Although the late administration of IL-4 activated
BMDM cells to mSOD1 did not significantly affect mouse survival
compared to control animals, a significant reduction in motor
ability was observed starting on day 127 through day 140, as
monitored by Rotarod performance (P,0.001, Student’s t test,
FIGURE 1C).
To monitor the in vivo homing of the injected IL-4-activated
BMDM cells, they were labeled with CFSE prior to injection.
CFSE-labeled IL-4 activated BMDM were detected in the spleens
of mSOD1 mice, while no cells were detected in the blood and
peripheral lymph nodes (LN) or CNS (FIGURE 1D). Importantly,
the survival of mSOD1 mice receiving repeated injections of
IFNc-activated BMDM starting from day 70 (early BMDMIFNc)
was not affected, and was similar to that of untreated control
mSOD1 littermates (FIGURE 1E). Furthermore, early treatment of
mSOD1 mice with IFNc-activated BMDM did not affect their
motor ability compared to control mice, as monitored by Rotarod
performance (data not shown). To evaluate the immune markers
and the suppressive function of IL-4-activated BMDM versus
IFNc-activated BMDM, also known as M2 and M1 myeloid cells,
respectively, we further characterized the isolated BMDM cells
from Cx3cr1
GFP/+ mice [17] following their treatment with IL-4 or
with IFNc, as described in Methods. Immunophenotyping of the
cytokine-treated and untreated BMDM cells revealed that they
were positive (.98%) for CD11b, CD115, and CX3C chemokine
receptor 1 (CX3CR1) also known as the fractalkine receptor
(Figure 2A–B). Measurement of activation markers revealed that
IL-4 activation resulted in higher expression of CD11c and lower
expression of MHCII, CD80 and CD86 compared to IFNc
treated cells (Figure 2C). As shown in Figure 2D, IL-4 activated
cells efficiently inhibited CD4 T cell antigen receptor-mediated
proliferation, while IFNc-activated (M1) myeloid cells had only a
slight effect on CD4 proliferation.
To ensure the in vivo suppressive potential of systemic
administration of the IL-4-activated BMDM, we used a mouse
model of multiple sclerosis, which represents an inflammatory T-
cell mediated CNS disease that can be arrested by systemic anti-
inflammatory treatment. Chronic EAE was induced in C57BL/6J
adult mice, and clinical signs were evaluated daily as described in
Methods. Animals were either injected (every fifth day) with non-
activated BMDM, or with IL-4-activated BMDM starting 9 days
after MOG vaccination. Systemic i.v administration of IL-4-
activated BMDM cells significantly reduced the severity score of
EAE compared to animals treated with non-activated BMDM
cells (2-factor repeated measures ANOVA; P,0.001; FIGURE 2E).
Thus, the immunosuppressive phenotype of the IL-4-activated
BMDM was verified by their suppressive effect in an inflammatory
disease model. These experiments showed that while elevated
levels of IL-4-activated BMDM had a beneficial impact on the
EAE model, in which their effect is manifested by inhibition of the
systemic autoimmune attack on the CNS, they had a negative
impact on mSOD1 mice, resulting in an earlier onset of the disease
symptoms and a shorter life expectancy.
To assess the relevance of such a cell population to ALS
patients, we examined whether ALS patients have higher levels of
myeloid-derived cells that could contribute to suppressor effect in
Survival of male mSOD1 mice receiving repeated injections of IFNc activated BMDM starting from day 70 (early BMDMIFNc) was similar (13061.4 days,
n=9) to untreated control mSOD1 littermates (13161.9 days, n=8).
doi:10.1371/journal.pone.0026921.g001
Circulating M2 Myeloid Cells in ALS and EAE
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e26921the circulation. To this end, we first collected whole peripheral
blood samples from 15 patients (mean age6SD, 55610 years,
n=15 11M, 4F) with the clinical diagnosis of definite ALS, and
from 10 healthy volunteers (52610 years, n=10, 6M, 4F) and
analyzed them by flow cytometry for the presence of circulating
myeloid-derived cells reminiscent of MDSCs, monocytes, granu-
locytes and T cells. The MDSCs in the patients were defined as
lineage negative/low (LIN
2/Low), HLA-DR negative, CD33
positive cells, based on previously described parameters [13]. A
higher percentage of circulating MDSCs out of total PBMCs was
observed in sALS patients relative to healthy volunteers
(mean6SD, 3.661.9 vs. 2.04%61, respectively; p=0.02). An
increased percentage of granulocytes from total leukocytes were
also found in sALS relative to healthy controls (54.768.7 vs.
46%68.9, respectively; p=0.025). Based on these initial results,
we analyzed additional patients; altogether, our studies included
Figure 2. IL-4 activated BMDM cells inhibit CD4 T cell activation and ameliorate EAE. Bone marrow derived myeloid cells (BMDM) were
cultured from Cx3cr1
GFP/+ mice (B6.129P- Cx3cr1tm1Litt/J, in which one of the CX3CR1 chemokine receptor alleles was replaced with a gene encoding
GFP [green fluorescent protein]), and treated with IL-4 or IFNc as described in Methods. (A) Acquired cells were first gated for live cells and the
fraction of cells expressing CD11b and Cx3cr1
GFP+ (high and low) was determined. (B) Histograms showing the expression levels of CD11c and CD115
within the CD11b
+ Cx3cr1
GFP+ cell population are shown. (C) Histograms showing the expression levels of MHCII, CD80 and CD86 within D11b+
Cx3cr1
GFP+ cells are shown. (D) Effect of BMDM on T cell proliferation in vitro. Total splenocytes were labeled with CFSE, stimulated with or without
anti-CD3 (1 mg/ml), and co-cultured with IL-4 or IFNc– activated BMDM cells. On day 3, cells were harvested and CFSE dilution in CD4 T cells
(CD4
+TCRb
+) was measured by flow cytometry. (E) Chronic EAE was induced in C57BL/6J mice. EAE scores in mice injected with IL-4-activated BMDM
(MOG+BMDMIL-4) (n=6) or with nonactivated BMDM (MOG+ BMDMMedium) (n=7), administered every 6
th day starting 9d after MOG vaccination are
shown. Intravenously injected IL-4-activated BMDM cells significantly improved clinical features in mice with chronic EAE compared to mice treated
with non-activated BMDM cells (2-factor repeated measures ANOVA; P,0.001; **P,0.01, ***P,0.001, Student’s t test).
doi:10.1371/journal.pone.0026921.g002
Circulating M2 Myeloid Cells in ALS and EAE
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e2692128 ALS patients and 22 control volunteers including 7 control
patients suffering from other diseases (TABLE 1). Representative
flow diagrams summarizing the phenotypic analysis of MDSCs are
shown in FIGURE 3A. MDSCs were defined as LIN
2/Low, HLA-
DR negative, CD33 positive cells (R3) out of gated PBMC. A 2-
fold increase in the percentage of circulating MDSCs in sALS
patients relative to all control subjects was observed (4.162.6 vs.
2.1%61.1, respectively; p=0.0013; FIGURE 3B). The higher
percentage of MDSCs was observed in sALS patients when we
compared them to healthy volunteers, or to patients with other
neurologic diseases (p=0.004, p=0.027, respectively; FIGURE 3C).
Further analysis of MDSCs revealed heterogeneous cell morphol-
ogy, suggesting that this population consists of two major cell types
(data not shown).
To evaluate whether the levels of MDSCs could serve as a
potential risk factor for ALS, an analysis of receiver operating
characteristics (ROC, specificity vs. sensitivity) was performed.
The analysis revealed that the optimal cutoff, which represented
the percentage of MDSCs out of PBMCs, to distinguish sALS
patients from all control subjects was 2.28 percent. This cutoff
value distinguished sALS patients from all control subjects with
82% accuracy, 86% sensitivity and 73% specificity (Figure S1A).
Using an identical cutoff, sALS patients were differentiated from
selected control subjects (n=20), excluding two patients diagnosed
with severe immunosuppression, with 86% accuracy, 86%
Figure 3. Higher percentage of circulating MDSCs in sALS patients relative to controls. (A) Representative flow diagrams from one ALS
patient are shown. Acquired cells were first gated (R1) based on the expression of CD45; this population was comprised of total peripheral
mononuclear cells (PBMCs). Acquired cells were then gated (R2) by selecting Lin
2/Low, HLA-DR negative cells. Within this population, the fraction of
cells expressing CD33 was determined (R3). The MDSC population was defined as Lin
2/Low, HLA DR negative, and CD33 positive cells. MDSC
percentage was calculated as the percentage of total CD45 positive PBMCs in the whole blood samples. (B) The percentage of circulating MDSC was
significantly higher in ALS patients compared with control donors (p=0.001); bar represents the median. (C) The proportion of MDSC in ALS patients
(n=28) was increased compared to both healthy controls (n=15; p=0.004) and to neurologic disease controls (n=5; p=0.027).
doi:10.1371/journal.pone.0026921.g003
Table 1. Characteristics of sALS patients and control subjects.
Characteristics of sALS patients sALS patients (n=28)
Age
a 56.569.7 years (37–73)
Sex M=19; F=9
Location of onset Spinal =79%; bulbar=21%
ALSFRS-R score (0–48)
b 28 (6–45)
Characteristics of controls Controls (n=22)
Age
a 58.9612 years (38–78)
Sex M=10; F=12
Healthy controls n=15
Neurologic disease controls n=5; 3 diagnosed with CIDP, 1 diagnosed




n=2; 1 with CVID, 1with COPD
aMean6SD (age range, years)
bMedian (range)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Common Variable Immuno-deficiency (CVID).
Chronic Obstructive Pulmonary Disease (COPD).
doi:10.1371/journal.pone.0026921.t001
Circulating M2 Myeloid Cells in ALS and EAE
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e26921sensitivity and 80% specificity (Figure S1B). There was no
correlation between the levels of MDSC and the age of each sALS
patient, nor with their ALSFRS score as a measure of disease
severity / stage (data not shown). A smaller group of sALS patients
(n=9) was assessed for MDSC levels 3 months after the initial
measurements. The individual patient characteristics are summa-
rized along with a representative flow diagram summarizing the
phenotypic analysis of MDSCs (Figure S2A–B). Although this
period was not sufficient to expect to see any change among a
population of patients who were not in synchrony in terms of
disease stage, ALSFRS score analysis indicated a decrease in
patient score at the second clinic visit compared with the first visit
(p=0.05, paired t test), with a trend associated with higher MDSC
levels (p=0.096, Figure S2C).
Discussion
In the present study, we showed in a mouse model of ALS that
disease course was exacerbated following systemic adoptive
transfer of IL-4-activated BMDM (M2 myeloid cells), which
suppress peripheral T cell activity. Such treatment in an animal
model of an inflammation-induced neurodegenerative disease,
EAE, provided a beneficial effect. These results strongly support
the contention that although these two CNS pathologies share
local inflammation, they respond in an opposite manner to
systemic anti-inflammatory treatment. Moreover, the negative
effect in ALS mice obtained with BMDM activated by IL-4, which
is known to be a strong inducer of Arginase 1, a characteristic
feature of MDSCs, was apparently consistent with the observed
elevation in the proportion of MDSCs in the peripheral blood of
ALS patients. Such MDSCs in cancer patients are known for their
ability to inhibit T cell activity [13,14]. Further studies are
necessary to confirm the in vitro suppressive function of ALS
patient’s MDSCs.
ALS is a neurodegenerative disease that selectively affects motor
neurons in the CNS, leading to bulbar, respiratory, and limb
weakness. The mouse model we used (mSODG93A) is the most
common model in the field of ALS for pre-clinical research. In the
present study, we evaluated the in vivo effect of excess peripheral
myeloid-derived anti-inflammatory cells on a disease progression.
The animal model of multiple sclerosis, EAE, was chosen here as a
control for the in vivo immunosuppressive effect of the anti-
inflammatory (M2) myeloid-derived cells. Multiple sclerosis, unlike
ALS, is a chronic inflammatory disease in its etiology, which leads
to cumulative and irreversible CNS damage [18]. We expected
that if these myeloid-derived suppressor cells (M2) would show a
suppressive effect in EAE, the outcome in ALS could be reliably
attributed to T cell immunosuppression in the peripheral immune
organs. A previous study reported an accumulation of Arg-I+-
MDSCs in the spinal cord during EAE; these cells were largely
restricted to the demyelinating plaque. The presence and density
of Arg-I+-cells, and the proportion of apoptotic but not
proliferative T cells, were correlated with the time course of
EAE; cell numbers peaked in parallel with the clinical score,
decreased significantly during the remitting phase, and completely
disappeared during the chronic phase [19].
It is accepted that ALS, although affecting motor neurons, non-
neuronal cells play critical roles in disease progression
[4,20,21,22]. The present study introduces an additional cell
population potentially involved in disease regulation, thereby
extending the scope of the players that have been identified in this
disease beyond the CNS, which includes circulating T cells, NKT
cells and monocytes [4,21,22,23,24]. In a model of acute spinal
cord injury, circulating T cells facilitate recruitment of monocytes to
the injured CNS that locally suppress the neurotoxic responses of
microglia [4]. Moreover, in both acute spinal cord injury and an
ALS mouse model, CD4
+ T cell deficiency accelerates the
degenerative process [4,22,25,26]. Our present results demonstrat-
ing that the increased levels of circulating IL-4-activated anti-
inflammatory BMDM that homed to the spleen (a peripheral
lymphoid organ) and presumably had a negative effect on the
availability of T cells, support the contention that circulating T cells
are needed for protecting the motor neurons, either by their direct
recruitment to the CNS or by facilitating infiltration of monocytes
that locally suppress the microglia. A previous study suggested an
increase expression of F/480 and Gr-1 in the perifollicular area of
spleen from SOD1 Tg mice compare to age-matched wild-type
controls [26]. The fact that late administration of anti-inflammatory
myeloid-derived cells to mSOD1 did not significantly affect their
survival compared to control mice, while the survival times of
mSOD1 mice receiving these cells at an early stage was significantly
shorter (by 14 days), suggests that either the disease is too advanced
to be affected or that the systemic immune response has already
been deteriorated at this stage, and thus any further addition of cells
is unlikely to have significant effect [26]. Thus, it appears that in the
advanced stage of the disease, the capacity of the remaining
circulating immune cells in these mice to support the CNS is
diminished, which might explain the lack of any further suppression
by the injected suppressor cells. Collectively, the fact that mSOD1
mice that received IL-4 activated BMDM showed earlier disease
symptoms, suggests that systemic immune suppression found in
patients could be viewed as co-morbidity factor in ALS. In cancer,
such cells have been linked with disease progression via a
mechanism induced by the tumor itself as a means of escaping
from immune surveillance and immune-mediated elimination
[20,27]. A recent study suggested up-regulation of a T cell co-
stimulation pathway and a key regulator of immune responses in
ALS mice and patients [28], possibly in response to increased
MDSC levels. Importantly, a significant reduction in the number of
thymic progenitor-cells and abnormal thymic histology was
observed in ALS mice [29]. Additionally, a reduction in blood
levels of T cell receptor rearrangement excision circles (sjTRECs),
as a measure of thymic output, and a restricted T cell repertoire
accompanied by an increase in pro-apoptotic markers in ALS
patients were demonstrated [29].
As MDSCs are one of the main circulating immunosuppressive
factors in cancer and other pathological conditions, several
different therapeutic strategies that target these cells are under
investigation. Some of the strategies include promoting myeloid
cell differentiation into non immunosuppressive lineages, inhibit-
ing their expansion, neutralizing their products, or elimination of
this population [12]. In summary, the finding from this study
uncover a possible risk factor and a novel target for therapeutic
intervention in ALS, while the same cell population limits the
inflammatory damage in a mouse model of MS. Interference with
the suppressive activity of MDSCs has been shown to restore
normal immune function in tumor-bearing hosts. Thus for
example, L-arginine metabolism in MDSCs might be an excellent
molecular target for a novel class of immunoregulatory com-
pounds in early ALS to restore immune function and increase the
efficacy of any immune-based therapy.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All subjects participating in this
study signed an informed consent form approved by the Methodist
Circulating M2 Myeloid Cells in ALS and EAE
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work was conducted according to national and international
guidelines and approved by Weizmann Institute’s Animal Care
and Use Committee (IACUCU; permission number: 03680806-1
and 03740707-2).
Animals
Inbred adult male C57BL/6J mice (8210 weeks old), ALS mice
[B6SJL-Tg (SOD1-G93A)1Gur/J; Jackson Laboratories, ME],
and their WT B6SJL littermates were used. Animals with ALS
were anesthetized when no longer able to right themselves within
30 seconds of being placed on their sides. Cx3cr1GFP/+ mice
were used as donors for BMDM cells (B6.129P- Cx3cr1tm1Litt/J,
in which one of the CX3CR1 chemokine receptor alleles is
replaced with a gene encoding GFP [green fluorescent protein]).
Patients and control individuals
Patients were enrolled from Methodist Hospital Muscular
Dystrophy/ALS clinic. ALS patients were not being treated with
riluzole during the study, and all provided written informed
consent. Peripheral whole blood was drawn from 28 sALS patients
(mean age 56; range 37–73) diagnosed with definite or probable
sporadic ALS according to revised El Escorial criteria of the World
Federation of Neurology [30] in order to identify biological
markers by flow cytometry. Additional peripheral blood samples
were donated by 22 control volunteers (mean age 59; range 38–78)
after giving written informed consent. The control volunteers
included 15 normal healthy volunteers without histories of
infectious diseases or other disorders, 5 neurologic disease controls,
and 2 non-neurologic disease controls. From each participant,
25 ml of venous blood was collected in K2 EDTA-lavender top
tubes (BD, Franklin Lakes, NJ). sALS patient and control group
characteristics are detailed in TABLE 1.
Antibodies and flow cytometry
Antibodies used for cell surface labeling of mouse BM myeloid
cells included PE or PercP-Cy5.5 conjugated CD11b (clone M1/
70; BioLegend), PercP conjugated CD86 (clone GL-1; BioLegend),
APC conjugated CD11c (clone N418; eBioscience), APC conju-
gated CD80 (clone 16-10A1; eBioscience), PE conjugated MHC-II
(clone N/MR-4; eBioscience) and PE conjugated CD115 (clone
AFS98; eBioscience). Flow cytometry was performed on each
sample using a BD Biosciences LSRII flow cytometer, and the
acquired data were analyzed using FlowJo software.
Antibodies used for cell surface labeling of human whole blood
leukocytes included FITC conjugated Lineage Cocktail 1 (LIN-
1)(CD3 clone SK7, CD14 clone MwP9, CD16 clone 3G8, CD19
clone SJ25C1, CD20 clone L27, CD56 clone NCAM16.2; BD
Biosciences), HLA-DR (PE-conjugated clone TU36; BD Biosci-
ences), CD45 (PercP--conjugated clone 2D1; BD Biosciences),
CD33 (APC conjugated LEU-M9; BD Biosciences), CD3 (FITC-
conjugated clone SK3; BD Biosciences), CD8 (PE-conjugated
clone SK1; BD Biosciences), CD4 (APC-conjugated clone SK7;
BD Biosciences), and appropriate isotype-matched control anti-
bodies (BD Biosciences). Staining was performed on fresh venous
blood collected in EDTA-coated vacutainer tubes (BD Bioscienc-
es). Briefly, 100 mL of whole blood was mixed with 5 mL of each
antibody used, in a BD Falcon
TM round-bottom tube. Samples
were incubated at room temperature for 30 minutes; then, each
sample was mixed with 2 mL of 1x erythrocyte lysis buffer (BD
Biosciences) and incubated for an additional 15 minutes to remove
red blood cells. Samples were spun at 1500 rpm for 5 minutes in a
refrigerated centrifuge, supernatants removed and washed with
FACS buffer (1% FBS in PBS, 0.09% sodium azide). Cell pellets
were then resuspended in 300 mL of FACS buffer. Flow cytometry
was performed on each sample using a BD Biosciences LSRII flow
cytometer. Acquired data were analyzed using FlowJo software.
CFSE inhibition assay
Total splenocytes (1*10
5 per well) were labeled with CFSE
(Molecular Probes) (2.5 mM in PBS for 10 min). Labeled cells were
washed twice to remove unbound CFSE, incubated with 1 mg/ml
anti-CD3 (145-2C11, eBioscience) and co-cultured in complete
medium for 72 hrs with untreated or with IL-4 or IFNc–activated
BMDM cells (5x10
4 per well). CFSE dilution in CD4 T cells
(CD4
+TCRb
+) was measured by flow cytometry.
Preparation of bone marrow-derived myeloid cells
Bone marrow cells were harvested from both the hindlimbs (tibia
and femur) and the forelimbs (humerus) of WT mice (8210 weeks
old) by flushing the bones with Dulbecco’s phosphate-buffered
saline (PBS; Sigma-Aldrich) under aseptic conditions. Cells were
collected and centrifuged (10 min, 1000 rpm, 4uC), resuspended,
and then seeded (7610
6 cells) in 10 ml of culture medium [RPMI-
1640 mediumsupplementedwith 10%fetalcalf serum,L-glutamine
(1 mM), sodium pyruvate (1 mM), b-mercaptoethanol (50 mM),
penicillin (100 U/ml) and streptomycin (100 U/ml)], and cultured
at 37uC/5% CO2 in 75-cm
2 tissue-culture flasks previously coated
withpoly-D-lysine(PDL)inboratebuffer(pH 8.4).Culturemedium
and floating cells were discarded every 4
th day, and fresh medium
was added. After 10 days of incubation, nonadherent cells were
washed out, and the flasks with remaining adherent cells were
refilled with fresh medium. The cells were then left untreated or
were treated for 2 days with 10 ng/ml of recombinant mouse IL-4
(endotoxin,0.1 ng permg, R&D Systems) or IFN-c (endotox-
in,0.1 ng permg, R&D Systems). On the day of injection, the
adherent cells were washed twice with cold PBS and placed on ice
for 10 min; then, the cells were removed using a cell scraper,
counted and injected (2610
5 cells in 100 ml of PBS) to the tail vein.
Purity of the cells was assessed by FACS analysis after staining with
antibodies (Abs) against Mac-1 (CD11b) (Pharmingen), and was
found to be .98%. For detection of BMDM cells following i.v
injection (Fig. 2D), cells were labeled with CFSE prior to injection:
2x10
6 BMDM cells (20x10
6 cells/mL) were incubated in PBS
(without Ca2+/Mg2+) supplemented with 5 mM CFSE (Molecular
Probes) for 8 min at 25uC. Following incubation, the cells were
washed three times with RPMI containing 8% fetal calf serum
(FCS). Then, 2x10
6 CFSE-labeled BMDM in 100 ml PBS were
injected into the tail vein of mSOD1 mice (120d, n=3). After 24 hr,
blood, spleen and peripheral LN were removed, and CD11b
+
CFSE
+ cells were analyzed by LSRII flow cytometer.
Assessment of mouse motor ability
Mice were inspected routinely for general condition. From 60 d
of age onward, mice were assessed for motor dysfunction using the
Rotarod apparatus (Jones and Roberts 7650, Ugo Basile, Italy).
Animals were placed on an accelerating rod, and time required for
each mouse to fall from the rod was recorded. Out of three trails,
the longest time taken for an animal to fall from the rod was
recorded and used for analysis. A cut-off time point of 180 sec was
defined, and mice remaining on the rod for at least this period of
time were deemed asymptomatic.
Induction and evaluation of acute and chronic EAE
To induce chronic EAE, adult male C57BL/6J mice were
injected s.c. with 200 mg (300 ml) of MOG35–55 (Sigma-Aldrich) in
incomplete Freund’s adjuvant containing 2.5 mg/ml M. tuberculosis
Circulating M2 Myeloid Cells in ALS and EAE
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Aldrich) was injected on the day of the immunization, and again 2
days later. Clinical signs were evaluated daily in a blinded fashion
by at least two investigators, and an EAE score was assigned (0,
healthy; 1, limb tail paralysis; 2, ataxia and/or paresis of hind
limbs; 3, paralysis of hind limbs and/or paresis of forelimbs; 4,
tetraparalysis; 5, moribund state or death).
Statistical analyses
The SPSS and SAS statistical packages were used to analyze all
data. Comparisons between sALS patient and control lympho-
cytes, monocytes and MDSC frequencies were analyzed using a
two tailed Student’s unpaired t test. The same analysis was also
used to assess the influence of age differences. Comparisons of
ALSFRS sALS patient scores and percent of MDSC were
analyzed using the two-tailed Student’s paired t test. Differences
in survival times were computed using Kaplan–Meier survival
statistics (log-rank-sum test; Number Cruncher Statistical Systems,
Kaysville, UT). Disease progression studies were analyzed using a
one-way analysis of variance (ANOVA) with repeated measures
(StatView software, v5; SAS Institute Inc.). Differences between
groups were analyzed using a two-way ANOVA (JMP software,
v5; SAS Institute, Cary, NC). Data from mouse studies are shown
as mean6standard error (SEM).
Supporting Information
Figure S1 The levels of circulating MDSCs as a
potential diagnostic marker for ALS. Receiver operating
characteristic (ROC) analysis curve indicating the prognostic
discriminatory power of the percentage of MDSCs/PBMC in ALS
patients, given a cutoff value of 2.28, compared with controls. A.
Compared with all control subjects (n=22), the overall area under
the curve (AUC) (left panel) was 0.82 [95% confidence interval
(CI): 0.698 to 0.945] with a sensitivity of 0.86 (95% CI: 0.67–0.96),
and specificity of 0.73 (95% CI: 0.5–0.89). B. Compared with
selected control subjects (n=20), excluding those with severe
immunosuppression (right panel), the AUC was 0.857 (95% CI:
0.745 to 0.97) with a sensitivity of 0.86 (95% CI: 0.67–0.96) and
specificity of 0.8 (95% CI: 0.5–0.89).
(TIF)
FigureS2 Relationship between the percentage of MDSCs
and ALSFRS-R score over time. A. Characteristics and main
c l i n i c a lf e a t u r e so fs A L Sp a t i e n t s( n = 9 )f r o mt w oc l i n i cv i s i t sa t3
month intervals. B. Fresh whole blood was incubated with a mixture
of LIN, HLA DR, CD33 and CD45 mAbs. MDSC populations are
shown in representative dot plots of sALS patients from two clinic
visits. Numbers indicate the percentage of LIN
2/Low,H L A - D R
negative, CD33 positive cells of total PBMC according to CD45/
SSC gating. C. The ALSFRS-R score was significantly lower
(p=0.05, paired T-test) in the second clinic visit compared with the
first visit, whilea clear trend to increased valuesinMDSC percentage
was observed (p=0.096, paired T-test).
(TIF)
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